TPG Inc. has retained advisors to explore a sale of Lyric Health, the healthcare software platform it assembled through bolt-on acquisitions since 2021, at a target valuation near $5 billion, according to sources with knowledge of the process. The firm has not committed to a sale and may retain the asset if bids disappoint. No timeline has been disclosed, though preliminary materials circulated in late March suggest a first-round deadline inside sixty days.

Lyric operates revenue cycle management and patient engagement software for mid-market hospitals and ambulatory surgery centers, processing roughly $18 billion in annual claims volume across 1,200 facilities. TPG built the platform by rolling up three regional players between 2021 and 2023, during the post-COVID healthcare IT buying frenzy when vertical SaaS traded at 12-15x forward revenue. Current comps sit closer to 8-10x, depending on recurring revenue mix and churn. If Lyric is running at $550-600 million in annualized revenue, the $5 billion ask implies a 8.3-9.1x multiple, which would place it at the upper end of today's range but well below what TPG likely underwrote three years ago.

The timing reflects two pressures. First, TPG's flagship fund that seeded the initial Lyric acquisition is entering its sixth year, the window where LPs expect distributions or marked progress toward exit. Second, the market for vertical healthcare software has bifurcated sharply. Large strategics like Oracle and Philips remain active acquirers but are prioritizing platforms with $1 billion-plus revenue and proven interoperability with Epic and Cerner. Private equity buyers are still present but pickier, and debt markets are pricing healthcare IT deals at 5.5-6.0x leverage, down from 7.0x in 2021. That compression makes it harder to engineer a return through a sponsor-to-sponsor sale unless Lyric shows durable growth above 20% annually.

Allocators should watch for two follow-on signals. First, whether TPG runs a full auction or negotiates directly with a shortlist of strategic buyers. A narrow process would suggest the firm believes valuation risk outweighs competitive tension. Second, whether any bids surface from growth-stage software roll-up shops like Thoma Bravo or Vista Equity, both of which have stepped back from healthcare IT in the past eighteen months. If neither engages, it signals the sector's return thresholds have moved beyond what bolt-on strategies can deliver. Expect clarity on buyer composition by late May.

The $5 billion figure, if it holds, would mark the largest pure-play revenue cycle management exit since Waystar's $2.7 billion take-private in 2019. It would also test whether TPG can extract a premium for operational improvements made since the roll-up, including a reported 15% reduction in customer acquisition cost and a shift toward annual prepaid contracts. If the deal prices below $4.5 billion, it confirms that vertical SaaS is no longer priced on narrative, only on audited cash flow and churn under 5% annually. That would reset expectations across the entire healthcare IT sponsor landscape and likely delay other planned exits until 2026.